ClariFind™

**WHO**
Patient’s physician, including the oncologist, pathologist, and/or surgeon, may request testing.

**WHAT**
Comprehensive Somatic Tumor Test (DNA). Next-generation sequencing assay covering all coding regions of 277 key cancer genes for both solid tumors and hematologic malignancies.

**HOW**
Employs next-generation sequencing (NGS) for comprehensive genomic profiling of a patient’s tumor sample.

**WHY**
To identify potential clinically actionable targets and associated therapies

- Diagnostic/disease classification
- Prognostic risk stratification
- Informs targeted treatment selection
- Clinical trial opportunities

**WHEN**
Difficult to treat cancers. Rare cancer types. Patients with metastatic, refractory, recurrent, and/or advanced stage cancers. Initial and serial follow-up profiling for hematologic malignancies including acute leukemia and myelodysplastic syndrome.

**WHERE**
Baylor Genetics in conjunction with Baylor College of Medicine, 20+ MDs and PhDs.

**SAMPLE TYPES**
Blood, bone marrow, FFPE, fresh tissue (frozen or in media), extracted DNA.

**WHY CLARIFind**

<table>
<thead>
<tr>
<th>Unique Molecular Index (UMI)</th>
<th>Allows for confident low-level variant detection (5% down to as low as 1%).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amplicon-based, single adapter ligation, single primer extension</td>
<td>Low DNA input requirement – key for small biopsy samples.</td>
</tr>
<tr>
<td>Optimized gene coverage</td>
<td>Improved coverage of GC-rich regions in genes such as CEBPA and CCND1.</td>
</tr>
<tr>
<td>Simplification</td>
<td>One panel for all cancer types and variety of sample types.</td>
</tr>
<tr>
<td>Reporting</td>
<td>Report highlights nearby clinical trials by zip code. Color coded and easy to navigate summary page.</td>
</tr>
<tr>
<td>Expertise</td>
<td>Interpretive summary provided by board-certified clinical experts who are available for clinical consultation.</td>
</tr>
</tbody>
</table>

**Main Competition**

- Capture-based chemistry
- DNA input not disclosed but presumably higher based on published sample requirements
- Separate tests for solid tumors and hematologic malignancies
- No interpretative summary provided
- No AMP/ASCO/CAP classification for variants provided
- Report does not highlight nearby clinical trials
- Higher cost

**ADDITIONAL TESTING RECOMMENDATIONS**

**Solid Tumors:** 180K CGH/SNP Array for genomic copy number analysis, Microsatellite Instability (MSI), HNPPC/Lynch Syndrome, by PCR, PD-L1 by immunohistochemistry.

**Non-Small Cell Lung Cancer:** ALK, MET, RET, and ROS1 FISH, PD-L1 by immunohistochemistry.

**Breast Cancer or Gastric Cancer:** ERBB2 (HER2/neu) FISH.

**Hematologic Malignancies:** FLT3 mutation testing by PCR for acute myeloid leukemia, CytoScan HD SNP Array for genomic copy number analysis, Classical chromosomal analysis.

**Aggressive/High-Grade B-Cell Lymphoma:** MYC, BCL2, and BCL6 FISH.

We offer other FISH panels and single probes and single gene molecular tests (please refer to requisition).